Assembling Au8 clusters on surfaces of bifunctional nanoimmunomodulators for synergistically enhanced low dose radiotherapy of metastatic tumor
-
Published:2024-01-05
Issue:1
Volume:22
Page:
-
ISSN:1477-3155
-
Container-title:Journal of Nanobiotechnology
-
language:en
-
Short-container-title:J Nanobiotechnol
Author:
Zhang Rui,Jia Mengchao,Lv Hongying,Li Mengxuan,Ding Guanwen,Cheng Ge,Li Juan
Abstract
Abstract
Background
Radiotherapy is one of the mainstays of cancer therapy and has been used for treating 65–75% of patients with solid tumors. However, radiotherapy of tumors has two limitations: high-dose X-rays damage adjacent normal tissue and tumor metastases cannot be prevented.
Results
Therefore, to overcome the two limitations of radiotherapy, a multifunctional core–shell R837/BMS@Au8 nanoparticles as a novel radiosensitizer were fabricated by assembling Au8NCs on the surface of a bifunctional nanoimmunomodulator R837/BMS nanocore using nanoprecipitation followed by electrostatic assembly. Formed R837/BMS@Au8 NP composed of R837, BMS-1, and Au8 clusters. Au8NC can enhance X-ray absorption at the tumor site to reduce X-ray dose and releases a large number of tumor-associated antigens under X-ray irradiation. With the help of immune adjuvant R837, dendritic cells can effectively process and present tumor-associated antigens to activate effector T cells, meanwhile, a small-molecule PD-L1 inhibitor BMS-1 can block PD-1/PD-L1 pathway to reactivate cytotoxic T lymphocyte, resulting in a strong systemic antitumor immune response that is beneficial for limiting tumor metastasis. According to in vivo and in vitro experiments, radioimmunotherapy based on R837/BMS@Au8 nanoparticles can increase calreticulin expression on of cancer cells, reactive oxygen species generation, and DNA breakage and decrease colony formation. The results revealed that distant tumors were 78.2% inhibited depending on radioimmunotherapy of primary tumors. Therefore, the use of a novel radiosensitizer R837/BMS@Au8 NPs realizes low-dose radiotherapy combined with immunotherapy against advanced cancer.
Conclusion
In conclusion, the multifunctional core–shell R837/BMS@Au8 nanoparticles as a novel radiosensitizer effectively limiting tumor metastasis and decrease X-ray dose to 1 Gy, providing an efective strategy for the construction of nanosystems with radiosensitizing function.
Funder
Jilin University Overseas Doctoral Class A Talent Start-up Project
Publisher
Springer Science and Business Media LLC
Subject
Pharmaceutical Science,Applied Microbiology and Biotechnology,Biomedical Engineering,Molecular Medicine,Medicine (miscellaneous),Bioengineering
Reference52 articles.
1. Chen Q, Chen J, Yang Z, Xu J, Xu L, Liang C, Han X, Liu Z. Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy. Adv Mater. 2019;31:1802228. 2. Sun W, Luo L, Feng Y, Cai Y, Zhuang Y, Xie R, Chen X, Chen H. Aggregation-induced emission gold clustoluminogens for enhanced low-dose x-ray-induced photodynamic therapy. Angew Chem Int Ed. 2020;59:9914–21. 3. Jia TT, Li BJ, Yang G, Hua Y, Liu JQ, Ma W, Zang SQ, Chen X, Zhao X. Enantiomeric alkynyl-protected Au10 clusters with chirality-dependent radiotherapy enhancing effects. Nano Today. 2021;39:101222. 4. Yoshimoto Y, Suzuki Y, Mimura K, Ando K, Oike T, Sato H, Okonogi N, Maruyama T, Izawa S, Noda SE. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS ONE. 2014;9:e92572. 5. Jia T, Yang G, Mo S, Wang Z, Li B, Ma W, Guo Y, Chen X, Zhao X, Liu J, Zang S. Atomically precise gold – levonorgestrel nanocluster as a radiosensitizer for enhanced cancer therapy. ACS Nano. 2019;13:8320–28.
|
|